AR090439A1 - Lipopeptidos antimicrobianos cortos - Google Patents
Lipopeptidos antimicrobianos cortosInfo
- Publication number
- AR090439A1 AR090439A1 ARP130100903A ARP130100903A AR090439A1 AR 090439 A1 AR090439 A1 AR 090439A1 AR P130100903 A ARP130100903 A AR P130100903A AR P130100903 A ARP130100903 A AR P130100903A AR 090439 A1 AR090439 A1 AR 090439A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- proline
- lipid
- acid
- lysine
- Prior art date
Links
- 230000000845 anti-microbial effect Effects 0.000 title abstract 3
- 108010028921 Lipopeptides Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract 3
- 150000002632 lipids Chemical class 0.000 abstract 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid ester group Chemical group C(CCCCCCCCCCC)(=O)O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 abstract 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 abstract 2
- 239000004474 valine Substances 0.000 abstract 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004475 Arginine Chemical group 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical group OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- 239000005639 Lauric acid Substances 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 235000021360 Myristic acid Nutrition 0.000 abstract 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 abstract 1
- 235000021314 Palmitic acid Nutrition 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 210000000214 mouth Anatomy 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Birds (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613212P | 2012-03-20 | 2012-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090439A1 true AR090439A1 (es) | 2014-11-12 |
Family
ID=47901428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100903A AR090439A1 (es) | 2012-03-20 | 2013-03-20 | Lipopeptidos antimicrobianos cortos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9278994B2 (enExample) |
| EP (1) | EP2827907B1 (enExample) |
| JP (1) | JP6261560B2 (enExample) |
| KR (1) | KR20140136494A (enExample) |
| CN (2) | CN104379177B (enExample) |
| AR (1) | AR090439A1 (enExample) |
| AU (1) | AU2013235692B2 (enExample) |
| CA (1) | CA2864179A1 (enExample) |
| DK (1) | DK2827907T3 (enExample) |
| ES (1) | ES2729237T3 (enExample) |
| MX (1) | MX2014011290A (enExample) |
| MY (1) | MY163100A (enExample) |
| PL (1) | PL2827907T3 (enExample) |
| RU (2) | RU2627648C2 (enExample) |
| SG (2) | SG10201607784VA (enExample) |
| TW (1) | TWI541254B (enExample) |
| WO (1) | WO2013142088A1 (enExample) |
| ZA (1) | ZA201405950B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10835572B2 (en) | 2014-06-30 | 2020-11-17 | Rohto Pharmaceutical Co., Ltd. | Composition for external application |
| JP6906274B2 (ja) * | 2014-06-30 | 2021-07-21 | ロート製薬株式会社 | 外用組成物、眼科用組成物、抗菌剤、及び抗菌方法 |
| US10660979B2 (en) * | 2015-08-26 | 2020-05-26 | The General Hospital Corporation | System and method for electrical control of bacteria |
| KR101855170B1 (ko) | 2015-11-18 | 2018-05-08 | (주)노바셀테크놀로지 | 신규 항균 펩타이드 및 그의 용도 |
| CN109320585B (zh) * | 2018-09-06 | 2021-10-26 | 南方医科大学 | 一种具有专一性抗痤疮丙酸杆菌作用及抗炎作用的短脂肽 |
| CA3112268A1 (en) * | 2018-09-12 | 2020-03-19 | The Governing Council Of The University Of Toronto | Indole-oxadiazole compounds and their therapeutic use |
| CN111035764B (zh) * | 2018-10-14 | 2021-09-07 | 深圳市健元医药科技有限公司 | 一种治疗类风湿性关节炎的组合物及其制备方法 |
| CN110279844A (zh) * | 2019-01-31 | 2019-09-27 | 浙江星杭泰乐生物医药有限公司 | 人工合成抗菌肽在制备抑菌消炎祛痘化妆品或外用药物制剂中的应用及抑菌消炎祛痘组合物 |
| CN111303242B (zh) * | 2020-02-27 | 2022-04-26 | 广州领晟医疗科技有限公司 | 一种KdPT的修饰肽 |
| KR102163568B1 (ko) * | 2020-08-21 | 2020-10-07 | 주식회사 비드테크 | 지방산 항균펩타이드 및 이를 함유하는 항균 조성물 |
| JP2023545899A (ja) * | 2020-09-29 | 2023-11-01 | ユニリーバー・アイピー・ホールディングス・ベー・フェー | アミノ酸を含むパーソナルケア組成物 |
| US11793746B2 (en) * | 2020-10-01 | 2023-10-24 | Chanda Zaveri | Intense skin hydration systems and methods |
| CN112679576B (zh) * | 2020-11-06 | 2022-09-20 | 黄石瀚海新材料科技有限公司 | 抗菌脂肽、抗菌脂肽水凝胶制备方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993008815A1 (en) * | 1991-10-28 | 1993-05-13 | Cytoven | Pharmaceutical dipeptide compositions and methods of use thereof |
| JP3273314B2 (ja) * | 1998-08-12 | 2002-04-08 | 独立行政法人農業生物資源研究所 | 抗菌ペプチド及びこれを有効成分とする抗菌剤 |
| US6492326B1 (en) | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
| DE10106852A1 (de) | 2001-02-14 | 2002-09-05 | T Luger | Entzündungshemmende Verbindungen |
| SE0300207D0 (sv) * | 2003-01-29 | 2003-01-29 | Karolinska Innovations Ab | New use and composition |
| EP1633380A4 (en) * | 2003-06-19 | 2010-08-11 | Yeda Res & Dev | ANTIMICROBIAL AND ANTICANCER LIPOPEPTIDES |
| JP4256389B2 (ja) | 2003-11-17 | 2009-04-22 | セダーマ | テトラペプチドとトリペプチドの混合物を含む組成物 |
| FR2870244B1 (fr) * | 2004-05-11 | 2011-01-07 | Centre Nat Rech Scient | Conjugues dipeptidiques antagonistes de l'alpha-msh |
| DE102004055541A1 (de) * | 2004-11-17 | 2006-05-18 | Henkel Kgaa | Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer Haut |
| US20100215726A1 (en) * | 2009-02-25 | 2010-08-26 | Peter Thomas Roth | Compositions for Diminishing the Appearance of Wrinkles |
| CN102329375A (zh) * | 2011-09-30 | 2012-01-25 | 中国药科大学 | 一组末端酰胺化的抗菌肽 |
-
2013
- 2013-03-07 WO PCT/US2013/029696 patent/WO2013142088A1/en not_active Ceased
- 2013-03-07 SG SG10201607784VA patent/SG10201607784VA/en unknown
- 2013-03-07 SG SG11201405244RA patent/SG11201405244RA/en unknown
- 2013-03-07 MX MX2014011290A patent/MX2014011290A/es unknown
- 2013-03-07 ES ES13710751T patent/ES2729237T3/es active Active
- 2013-03-07 RU RU2014142038A patent/RU2627648C2/ru not_active IP Right Cessation
- 2013-03-07 PL PL13710751T patent/PL2827907T3/pl unknown
- 2013-03-07 CN CN201380014970.0A patent/CN104379177B/zh active Active
- 2013-03-07 KR KR1020147028361A patent/KR20140136494A/ko not_active Ceased
- 2013-03-07 CA CA2864179A patent/CA2864179A1/en not_active Abandoned
- 2013-03-07 JP JP2015501713A patent/JP6261560B2/ja not_active Expired - Fee Related
- 2013-03-07 CN CN201710009878.5A patent/CN107080831A/zh active Pending
- 2013-03-07 US US14/385,517 patent/US9278994B2/en active Active
- 2013-03-07 MY MYPI2014002316A patent/MY163100A/en unknown
- 2013-03-07 DK DK13710751.2T patent/DK2827907T3/da active
- 2013-03-07 EP EP13710751.2A patent/EP2827907B1/en active Active
- 2013-03-07 AU AU2013235692A patent/AU2013235692B2/en not_active Ceased
- 2013-03-07 RU RU2017127273A patent/RU2017127273A/ru not_active Application Discontinuation
- 2013-03-19 TW TW102109748A patent/TWI541254B/zh not_active IP Right Cessation
- 2013-03-20 AR ARP130100903A patent/AR090439A1/es unknown
-
2014
- 2014-08-13 ZA ZA2014/05950A patent/ZA201405950B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013235692A1 (en) | 2014-09-25 |
| MX2014011290A (es) | 2014-10-13 |
| WO2013142088A1 (en) | 2013-09-26 |
| TWI541254B (zh) | 2016-07-11 |
| RU2017127273A (ru) | 2019-02-04 |
| ZA201405950B (en) | 2017-08-30 |
| HK1204453A1 (en) | 2015-11-20 |
| JP2015512386A (ja) | 2015-04-27 |
| JP6261560B2 (ja) | 2018-01-17 |
| CN107080831A (zh) | 2017-08-22 |
| EP2827907A1 (en) | 2015-01-28 |
| ES2729237T3 (es) | 2019-10-31 |
| TW201339176A (zh) | 2013-10-01 |
| MY163100A (en) | 2017-08-04 |
| RU2627648C2 (ru) | 2017-08-09 |
| US9278994B2 (en) | 2016-03-08 |
| US20150080291A1 (en) | 2015-03-19 |
| AU2013235692B2 (en) | 2016-12-08 |
| KR20140136494A (ko) | 2014-11-28 |
| EP2827907B1 (en) | 2019-03-06 |
| DK2827907T3 (da) | 2019-06-11 |
| SG10201607784VA (en) | 2016-11-29 |
| RU2014142038A (ru) | 2016-05-10 |
| PL2827907T3 (pl) | 2019-08-30 |
| CN104379177A (zh) | 2015-02-25 |
| CA2864179A1 (en) | 2013-09-26 |
| CN104379177B (zh) | 2017-07-04 |
| SG11201405244RA (en) | 2014-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090439A1 (es) | Lipopeptidos antimicrobianos cortos | |
| ES2572260T3 (es) | Péptidos útiles en el tratamiento y/o cuidado de la piel y/o membranas mucosas y su uso en composiciones cosméticas o farmacéuticas | |
| CO2021014694A2 (es) | Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio | |
| ES2682670T3 (es) | Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas | |
| MX2020013592A (es) | Composiciones para el cuidado bucal y metodos de uso. | |
| UY33047A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| AR080891A1 (es) | Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| MX2020001083A (es) | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. | |
| BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| EA201170190A1 (ru) | Фармацевтическая композиция, содержащая экстракт мозга свиньи | |
| BR112014021653A2 (pt) | Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| MX2019005979A (es) | Peptidos modificados. | |
| EP2934380A4 (en) | FIBRO-INTEGRATED HYDROGELS FOR TISSUE TISSUE TREATMENT | |
| BR112013024265A2 (pt) | peptídeo cíclico, uso de peptídeos cíclicos, método para o tratamento de doenças, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica | |
| MX395112B (es) | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. | |
| EA201892320A1 (ru) | Способ лечения или предупреждения остеоартрита | |
| MX377333B (es) | Peptidos derivados de ezrina y composiciones farmaceuticas de los mismos. | |
| AR101416A1 (es) | Terapias de antibióticos de péptidos derivados del búfalo de agua | |
| AR098615A1 (es) | Péptido para el tratamiento de hipoglicemia severa | |
| AR084095A1 (es) | Peptidos tomm34 y vacunas que los incluyen | |
| AR098616A1 (es) | Péptido para el tratamiento de hipoglicemia severa | |
| BR112013000296A2 (pt) | agentes terapêuticos 976 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |